Cancer after stem cell transplant for autoimmune disease
Part of Cancer, Immune system & allergy clinical trials.
This study looks at people who had a stem cell transplant for an autoimmune disease and later developed cancer. Researchers want to understand this complication better by reviewing medical records from France and Canada.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were 18 or older when you got your stem cell transplant.
- It was your first stem cell transplant for an autoimmune disease.
- Your transplant happened between January 1, 2000 and December 31, 2022.
- You gave permission for your medical information to be in a research registry in France (MATHEC-SFGM-TC) or Canada (Ottawa or Calgary databases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your body processes medications after a stem cell transplant from a donor. It aims to find the best way to test your genes to improve future treatments.
This study collects medical information from people with certain non-cancer conditions who receive a stem cell transplant. It may help doctors better understand transplant outcomes and care, since the study focuses on data collection rather than adding new treatment.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
This observational study follows people who had a stem cell transplant a few months ago to better understand risk for chronic graft-versus-host disease. You won’t get a study treatment; instead, you’ll complete questionnaires over time, and the study team looks at your symptoms and experiences.
This study checks whether the PASCA health program helps reduce complications in people with multiple myeloma after their first stem cell transplant. It may help by improving how patients manage side effects during recovery and ongoing treatment.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.